The unprecedented COVID-19 pandemic spanning over three years claimed millions of lives worldwide and caused immense misery to the humanity. Rapid developments of vaccines...
A new global network of laboratories for coronaviruses, CoViNet, has been launched by WHO. The aim behind this initiative is to bring together surveillance...
Following assessment and approval by the European Medicines Agency (EMA), WHO has issued an emergency use listing (EUL) for Nuvaxovid on 21 December 2021. Earlier on...
Evidences so far suggest that Omicron variant of SARS-CoV-2 has high transmission rate but fortunately is low on virulence and is not usually leading...
Single dose of the vaccine can increase vaccine coverage rapidly which is an imperative in many countries where level of vaccine uptake is not optimal.
WHO...
Sotrovimab, a monoclonal antibody already approved for mild to moderate COVID-19 in several countries gets approval by MHRA in the UK. This antibody was intelligently designed...
Three adenoviruses used as vectors to produce COVID-19 vaccines, bind to platelet factor 4 (PF4), a protein implicated in the pathogenesis of clotting disorders.
Adenovirus...
In order to raise levels of protection across the population against the Omicron variant, the Joint Committee on Vaccination and Immunisation (JCVI)1 of UK has...
The technology used by Cuba to develop protein-based vaccines against COVID-19 can lead to development of vaccines against new mutated strains in a relatively...